Genetic obesity

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:77828
Who is this for?
Show terms as
1FDA treatments18Active trials93Specialists8Treatment centers1Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Genetic obesity refers to a group of rare conditions where changes (mutations) in specific genes cause a person to gain significant weight, often starting in early childhood. Unlike common obesity, which is influenced by many lifestyle and environmental factors, genetic obesity is driven primarily by inherited changes in genes that control hunger, fullness, and how the body stores energy. These genes often affect a brain pathway called the melanocortin-4 receptor (MC4R) pathway, which plays a key role in telling your body when you are full. People with genetic obesity typically feel extremely hungry all the time — a condition called hyperphagia — and this intense, uncontrollable hunger makes it very hard to manage weight through diet alone. The condition can also cause hormonal problems, developmental delays, and in some forms, additional features like vision loss, intellectual disability, or heart problems depending on the specific gene involved. Treatment has improved significantly in recent years. Lifestyle changes and behavioral support remain important, but several FDA-approved medications now target the specific biological pathways involved. Early diagnosis is critical because it opens the door to targeted treatments that can dramatically improve quality of life. Genetic counseling is strongly recommended for affected individuals and their families.

Key symptoms:

Extreme, constant hunger that is very hard to satisfy (hyperphagia)Rapid and significant weight gain starting in infancy or early childhoodObesity that does not respond well to diet and exercise aloneLow energy levels and fatigueHormonal problems such as low thyroid function or delayed pubertyIn some forms: vision problems or blindnessIn some forms: intellectual disability or learning difficultiesIn some forms: kidney problemsIn some forms: extra fingers or toes (polydactyly)Emotional and behavioral challenges related to constant hungerSleep problems including sleep apneaJoint pain due to excess body weightHigh blood sugar or type 2 diabetes at a young ageHigh blood pressure and cholesterol

Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Childhood

Begins in childhood, roughly ages 1 to 12

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Sep 2026Inherited and Environmental Risks Acting on Body Weight

University of Washington — NA

TrialNOT YET RECRUITING
Jun 2026Study of Genetics in Childhood Obesity

Georgina Yan

TrialNOT YET RECRUITING
Apr 2026A Natural History of Genetic and Environmental Predictors of Pubertal Timing Among Youth With Obesity

National Institute of Environmental Health Sciences (NIEHS)

TrialNOT YET RECRUITING
Jan 2026Assessing Obesity Related Risk Factors in Adult Population: A Genetic and Behavioral Study

Augusta University — NA

TrialENROLLING BY INVITATION
Nov 2025International Genetic Obesity Registry

University of Ulm

TrialRECRUITING
Oct 2025Better4All Personalized Intervention

Harokopio University — NA

TrialNOT YET RECRUITING
Sep 2025The Resistant Starch Intervention for Cognitive Enhancement

Second Affiliated Hospital, School of Medicine, Zhejiang University — NA

TrialNOT YET RECRUITING
Jun 2025Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity

Second Affiliated Hospital, School of Medicine, Zhejiang University — NA

TrialRECRUITING
Jun 2025Better4All Personalized Intervention Pilot Study

Harokopio University — NA

TrialRECRUITING
May 2025The Causal Role of Ketone Bodies in Obesity-associated Disease Prevention - Combining Genetic Epidemiology With a Randomised Trial to Infer Causality

University of Bath — NA

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

1 available

WEGOVY

SEMAGLUTIDE· Novo Nordisk■ Boxed Warning

To reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity

Clinical Trials

18 recruitingView all trials with filters →
Phase 31 trial
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway
Phase 3
Active
PI: David Meeker, MD (Rhythm Pharmaceuticals, Inc.) · Sites: Phoenix, Arizona; Scottsdale, Arizona +54 more · Age: 665 yrs
Phase 41 trial
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
Phase 4
Actively Recruiting
PI: Judith Korner, MD,PhD (Columbia University) · Sites: New York, New York · Age: 1865 yrs
N/A5 trials
Genetic Risk, Parental Feeding Practices, and Appetitive Traits in Early Life
N/A
Actively Recruiting
PI: Jennifer Emond, PhD (Dartmouth College) · Sites: Hanover, New Hampshire
Impact of Genetic Polymorphisms And DASH Diet On Weight Loss Progression In Climacteric Women With Metabolic Syndrome
N/A
Actively Recruiting
· Sites: Rio de Janeiro · Age: 4060 yrs
Real-life Evaluation of WEGOVY (Semaglutide) Treatment in Adults With Monogenic Obesity (ObGeSema)
N/A
Actively Recruiting
PI: Christine POITOU-BERNERT, MD,PhD (Assistance Publique Hopitaux de Paris) · Sites: Paris; Paris · Age: 1899 yrs
A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considering Key Genetic and Sociodemographic Risk Factors
N/A
Actively Recruiting
PI: Elena Ladas, PhD, RD (Columbia University) · Sites: New York, New York · Age: 521 yrs
Genetics of the Acute Response to Oral Semaglutide
N/A
Actively Recruiting
PI: Lukasz Szczerbinski, MD, PhD (Clinical Research Centre, Medical University of Bi) · Sites: Bialystok, Podlaskie Voivodeship · Age: 1865 yrs
Other11 trials
Genetics of Obesity in Chinese Youngs
Actively Recruiting
PI: Guang Ning, MD.PhD (Shanghai Jiao Tong University School of Medicine) · Sites: Shanghai, Shanghai Municipality · Age: 1430 yrs
Dietary, Physiological, Genetic, and Behavioral Predictors of Health in a Young, Ethnically-Mixed Population
Active
PI: Peter Katzmarzyk, Ph.D. (Pennington Biomedical Research Center) · Sites: Baton Rouge, Louisiana · Age: 2035 yrs
Genetic Determinants of Kidney Disease in People of African Ancestry With HIV
Active
PI: Frank A Post (King's College Hospital NHS Trust) · Sites: London · Age: 1899 yrs
Meal Timing, Genetics and Weight Loss
Actively Recruiting
PI: Marta Garaulet, PHD (Universidad de Murcia) · Sites: Murcia · Age: 1899 yrs
Generation Victoria Cohort 2020s: A Statewide Longitudinal Cohort Study of Victorian Children and Their Parents
Actively Recruiting
PI: Melissa Wake, MBChB, FRACP, FAHMS, MD (Murdoch Childrens Research Institute) · Sites: Parkville, Victoria
Periodontal Assessment of a Bariatric Care Population
Actively Recruiting
PI: Nikolaos Donos, Prof. (Professor of Periodontology and Implantology) · Sites: London; London +2 more · Age: 1899 yrs
A Biological Atlas of Severe Obesity (Biological Tissue Collection)
Actively Recruiting
PI: Francois PATTOU, MD PhD (University Hospital, Lille) · Sites: Lille, Nord · Age: 1865 yrs
International Genetic Obesity Registry
Actively Recruiting
· Sites: Ulm
Evaluation Of DNA Methylation Pattern In Healthy, Sarcopenic, Obese And Sarcopenic Obese Older Women: A Cross-Sectional Study
Active
· Sites: Ribeirão Preto, São Paulo · Age: 6075 yrs
Study to Investigate Genetic Causes of Severe Early Childhood Onset Obesity.
Actively Recruiting
PI: Vidhu Thaker, M.D. (Columbia University) · Sites: Boston, Massachusetts; New York, New York · Age: 080 yrs
Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2
Actively Recruiting
PI: Tomoshige Hayashi, MD, PhD (Osaka Metropolitan University) · Sites: Sakai, Osaka · Age: 2099 yrs

Specialists

Showing 25 of 93View all specialists →
WP
Winfried Rief, PhD
Specialist
PI on 1 active trial
NP
Nikolaos Donos, Prof.
Specialist
PI on 1 active trial
JF
Javier Sánchez Sánchez, Full
Specialist
PI on 1 active trial
FP
Fiona Lithander, BSc, PhD
Specialist
PI on 1 active trial
RP
Rena Wing, Ph.D.
Specialist
PI on 1 active trial
KM
Karen Shaver, MS
WINSTON SALEM, NC
Specialist
PI on 2 active trials
JP
Jeanne McCaffery, Ph.D.
Specialist
PI on 1 active trial
RM
Robert L Hanson, M.D.
Specialist
PI on 2 active trials
HP
Helen M Roche, BSc, MSc, PhD
Specialist
PI on 1 active trial
CM
Christine POITOU-BERNERT, MD,PhD
Paris
Specialist

Rare Disease Specialist

LM
Laurent Servais, MD
Specialist
PI on 6 active trials1 Genetic obesity publication
KM
Kevin Patrick, MD, MS
MILWAUKIE, OR
Specialist
PI on 3 active trials
RP
Robert J Petrella, MD, PhD
BOSTON, MA
Specialist
PI on 2 active trials
EM
Eric Hollander, MD
Specialist
PI on 5 active trials
CM
Christina Wang, MD
Specialist
PI on 3 active trials
YP
Yannis Manios, Professor
Specialist
PI on 2 active trials
MP
Maria Gorska, Prof.
Specialist
PI on 1 active trial
EP
Edyta Adamska-Patruno, PhD
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

1 resources
WEGOVY(SEMAGLUTIDE)Novo Nordisk

Travel Grants

No travel grants are currently matched to Genetic obesity.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Genetic obesityForum →

No community posts yet. Be the first to share your experience with Genetic obesity.

Start the conversation →

Latest news about Genetic obesity

1 articles
NewsFDAMar 19, 2026
FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide
The U.S. Food and Drug Administration today approved a new higher dose (7.2 mg) of Wegovy (semaglutide) injection for weight loss and long-term maintenance of w
See all news about Genetic obesity

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Which specific gene mutation is causing my (or my child's) obesity, and what does that mean for treatment options?,Is my child eligible for setmelanotide (Imcivree) or any other targeted medication based on their genetic diagnosis?,Should other family members be tested for the same gene mutation?,What specialists should be part of our care team, and how often should we have check-ups?,Are there any clinical trials or new treatments we should know about for this specific gene mutation?,How can we manage the constant hunger at home and at school in a safe and practical way?,What are the long-term health risks we need to monitor for, and how can we reduce them?

Common questions about Genetic obesity

What is Genetic obesity?

Genetic obesity refers to a group of rare conditions where changes (mutations) in specific genes cause a person to gain significant weight, often starting in early childhood. Unlike common obesity, which is influenced by many lifestyle and environmental factors, genetic obesity is driven primarily by inherited changes in genes that control hunger, fullness, and how the body stores energy. These genes often affect a brain pathway called the melanocortin-4 receptor (MC4R) pathway, which plays a key role in telling your body when you are full. People with genetic obesity typically feel extremely

At what age does Genetic obesity typically begin?

Typical onset of Genetic obesity is childhood. Age of onset can vary across affected individuals.

Are there clinical trials for Genetic obesity?

Yes — 18 recruiting clinical trials are currently listed for Genetic obesity on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Genetic obesity?

25 specialists and care centers treating Genetic obesity are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.